Exclusive Summary

• With significantly lower drug interaction risks compared to omeprazole, it is the preferred PPI therapy for patients co-prescribed with cardiovascular drugs like clopidogrel.
• The global prevalence of GERD approaches 14%, ensuring a massive, rigid, and continuously expanding lifelong market demand for this first-line treatment.
• The original patents have long expired, allowing the highly scaled Chinese supply chain to provide disruptive cost advantages and exceptionally lucrative margins for overseas distributors.
• Supplying complete specifications of 20mg and 40mg enteric-coated capsules combined with full CTD dossier support empowers distributors to achieve rapid local regulatory approval and market launch.